Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
Precision BioSciences Inc. (DTIL) filed this Current Report on Form 8-K on January 18, 2024, to disclose the results of a Special Meeting of stockholders held on that date. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a corporate governance report regarding stockholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
The primary event reported is the approval of two proposals by stockholders. A total of 83,328,647 shares were present, representing approximately 68.34% of outstanding common stock.
- Proposal 1: Approval of amendments to the certificate of incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-30, as determined by the Board.
- Votes For: 71,771,593
- Votes Against: 11,275,251
- Votes Abstained: 281,803
- Broker Non-Votes: 0
- Proposal 2: Approval of an adjournment of the Special Meeting if necessary to solicit additional proxies.
- Votes For: 75,291,080
- Votes Against: 7,698,338
- Votes Abstained: 339,229
- Broker Non-Votes: 0
Both proposals received the affirmative vote of a majority of the voting power cast. Although Proposal 2 was approved, adjournment was not necessary as Proposal 1 was successfully passed.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the context of the reverse stock split authorization. The reverse stock split is intended to address the company's stock price, though specific reasons are not detailed in this excerpt.
Key Facts for Investor Verification
- Stockholders have authorized a reverse stock split with a ratio between 1-for-10 and 1-for-30.
- The Board of Directors retains discretion to determine the specific ratio within the approved range.
- The Board also retains the authority to abandon the amendments if necessary.
- The company is classified as an emerging growth company.